Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture

Current Pharmaceutical Design

Volumn 21, Issue 28, 2015, Pages 4000-4006

  Fraga Silva, Rodrigo A ^a   Trachet, Bram ^a,b   Stergiopulos, Nikolaos ^a  

^a EPFL   (Switzerland)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Abdominal aortic aneurysm; Interleukin 1 ; Renin angiotensin system; Statins; Tetracyclines

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; RENIN INHIBITOR; TETRACYCLINE DERIVATIVE; UROCORTIN II;

ABDOMINAL AORTA ANEURYSM; ANTIANGIOGENIC THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG INDICATION; DRUG TARGETING; ELECTIVE SURGERY; HUMAN; NONHUMAN; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURGICAL RISK; ABDOMINAL AORTA; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84947748834     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150826095346     Document Type: Review

References (105)

1. Michel JB, Martin-Ventura JL, Egido J, et al. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res 2011; 90(1): 18-27.
2. Sakalihasan NR, Limet OD. Defawe, Abdominal aortic aneurysm. Lancet 2005; 365(9470): 1577-89.
3. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110(5): 625-32.
4. Thompson RW, Liao S, Curci JA. Vascular smooth muscle cell apoptosis in abdominal aortic aneurysms. Coron Artery Dis 1997; 8(10): 623-31.
5. Malekzadeh S, Fraga-Silva RA, Trachet B, Montecucco F, Mach F, Stergiopulos N. Role of the renin-angiotensin system on abdominal aortic aneurysms. Eur J Clin Invest 2013; 43(12): 1328-38.
6. Lederle FA, Wilson SE, Johnson GR. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346(19): 1437-44.
7. Baxter BT, MC. Terrin, RL. Dalman, Medical management of small abdominal aortic aneurysms. Circulation 2008; 117(14): 1883-9.
8. Kurosawa K, JS. Matsumura, D. Yamanouchi, Current status of medical treatment for abdominal aortic aneurysm. Circ J 2013; 77(12): 2860-6.
9. Prospective Studies Collaboration1, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829- 39.
10. Manning MW, Cassi LA, Huang J, Szilvassy SJ, Daugherty A. Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease. Vasc Med 2002; 7(1): 45-54.
11. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 2010; 18(6): 298- 304.
12. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241(1): 92-101.
13. Mastoraki ST, Toumpoulis IK, Anagnostopoulos CE, et al. Treatment with simvastatin inhibits the formation of abdominal aortic aneurysms in rabbits. Ann Vasc Surg 2012. 26(2): 250-8.
14. Nagashima H, Aoka Y, Sakomura Y, et al, A 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36(1): 158-63.
15. Evans J, Powell JT, Schwalbe E, Loftus IM, Thompson MM. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 2007; 34(3): 302-3.
16. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32(1): 21-6.
17. Schlösser FJ, Tangelder MJ, Verhagen HJ, et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008; 47(6): 1127-33.
18. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. et al, Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006; 97(2): 279-80.
19. Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010. 159(2): 307-13.
20. Takagi H, Yamamoto H, Iwata K, et al. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and metaregression of observational comparative studies. Eur J Vasc Endovasc Surg 2012; 44(3): 287-92.
21. Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2011; 98(3): 346-53.
22. Sweeting MJ, Thompson SG, Brown LC, et al. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012; 99(5): 655-65.
23. Bader, M, Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439-65.
24. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 1997; 59: 395-412.
25. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52(3): 415-72.
26. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105(11): 1605-12.
27. Daugherty, A. Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci 1999; 892: 108-18.
28. Daugherty, A, L.A. Cassis, H. Lu, Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B 2011; 12(8): 624-8.
29. Trachet B, Fraga-Silva RA, Piersigilli A et al, Dissecting abdominal aortic aneurysm in Ang II-infused mice: suprarenal branch ruptures and apparent luminal dilatation. Cardiovasc Res 2015; 105(2): 213- 22.
30. Schriefl AJ, Collins MJ, Pierce DM, et al. Remodeling of intramural thrombus and collagen in an Ang-II infusion ApoE-/- model of dissecting aortic aneurysms. Thromb Res 2012; 130(3): e139-46.
31. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001; 134(4): 865- 70.
32. Inoue N, Muramatsu M, Jin D et al, Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient mice. J Atheroscler Thromb 2009; 16(3): 164-71.
33. Iida Y, Xu B, Schultz GM, et al. Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms. PLoS One 2012; 7(12): e49642.
34. Liao S, Miralles M, Kelley BJ, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33(5): 1057-64.
35. Fujiwara Y, Shiraya S, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 2008; 22(6): 703-8.
36. Kanematsu Y, Kanematsu M, Kurihara C, et al. Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. Hypertension 2010; 55(5): 1267-74.
37. Cassis LA, Gupte M, Thayer S, et al. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 2009; 296(5): H1660-5.
38. Saraff K, Babamusta F, Cassis LA, et al. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin IIinfused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23(9): 1621-6.
39. Daugherty A, Rateri DL, Charo IF, et al. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) 2010; 118(11): 681-9.
40. Ishibashi M, Egashira K, Zhao Q, et al. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24(11): e174-8.
41. Iida Y, Xu B, Xuan H, et al. Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol 2013; 33(4): 718-26.
42. Jaimes EA, Tian RX, Pearse D, Raij L. Up-regulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species. Kidney Int 2005; 68(5): 2143-53.
43. King VL, Trivedi DB, Gitlin JM, et al. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006; 26(5): 1137-43.
44. Gitlin JM, Trivedi DB, Langenbach R, et al. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 2007; 73(1): 227-36.
45. Bruemmer D, Collins AR, Noh G, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003; 112(9): 1318-31.
46. O'Regan A, Berman JS. Osteopontin: a key cytokine in cellmediated and granulomatous inflammation. Int J Exp Pathol 2000; 81(6): 373-90.
47. Freestone T, Turner RJ, Coady A, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995; 15(8): 1145-51.
48. Eagleton MJ, Ballard N, Lynch E, et al. Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during Angiotensin II induced aneurysm formation. J Surg Res 2006; 135(2): 345-51.
49. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23(3): 483-8.
50. Wang S, Zhang C, Zhang M, et al. Activation of AMP-activated protein kinase alpha2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. Nat Med 2012; 18(6): 902-10.
51. Virdis A, Neves MF, Amiri F, et al. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004; 22(3): 535-42.
52. Satoh K, Nigro P, Matoba T, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009; 15(6): 649-56.
53. Gavrila D, Li WG, McCormick ML, et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25(8): 1671-7.
54. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptormediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40(4): 516-20.
55. Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens 2010; 28 Suppl 1: S50-5.
56. Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 2012; 21(2): 142-6.
57. Savoia C, D'Agostino M, Lauri F, Volpe M. Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens 2011; 20(2): 125-32.
58. Habashi JP, Doyle JJ, Holm TM. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011; 332(6027): 361-5.
59. Daugherty A, Rateri DL, Howatt DA, Charnigo R, Cassis LA. PD123319 augments angiotensin II-induced abdominal aortic aneurysms through an AT2 receptor-independent mechanism. PLoS One 2013; 8(4): e61849.
60. Lautner RQ1, Villela DC, Fraga-Silva RA, et al, Discovery and characterization of alamandine: a novel component of the reninangiotensin system. Circ Res 2013; 112(8): 1104-11.
61. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87(5): E1-9.
62. Vickers C1, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277(17): 14838-43.
63. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens 2011; 20(1): 1-6.
64. Fraga-Silva RA, Ferreira AJ, Dos Santos RA. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1- 7)/mas receptor pathway in hypertension. Curr Hypertens Rep 2013; 15(1): 31-8.
65. Ferreira AJ1, Murça TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012; 2012: 147825.
66. Ferreira AJ, Santos RA, Bradford CN, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010; 55(2): 207- 13.
67. Thatcher SE. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2014; 34(12): 2617-23.
68. Danser AH. Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc Pharmacol 2007; 50(2): 105-11.
69. Seto SW. Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model. Clin Sci (Lond) 2014; 127(2): 123-34.
70. Davis V, Persidskaia R, Baca-Regen L, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998; 18(10): 1625-33.
71. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23(2): 336-46.
72. Prall AK. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002; 35(5): 923-9.
73. Vinh A. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J Vasc Res 2008; 45(2): 143-52.
74. Curci JA. Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28(6): 1082-93.
75. Xie X. Doxycycline does not influence established abdominal aortic aneurysms in angiotensin II-infused mice. PLoS One 2012; 7(9): e46411.
76. Curci JA. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31(2): 325-42.
77. Baxter BT. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36(1): 1-12.
78. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34(4): 606-10.
79. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126(6): 441-9.
80. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 2003; 38(6): 1376-83.
81. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JH. Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg 2009; 49(3): 741-9.
82. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009; 119(16): 2209-16.
83. Meijer CA, Stijnen T, Wasser MN, et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 2013; 159(12): 815-23.
84. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011; 41(5): 1203-17.
85. Johnston WF. Genetic and pharmacologic disruption of interleukin- 1beta signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2013; 33(2): 294-304.
86. Juvonen J. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997; 17(11): 2843-7.
87. Pearce WH. Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas. J Vasc Surg 1992; 16(5): 784-9.
88. Vijaynagar B. Potential role for anti-angiogenic therapy in abdominal aortic aneurysms. Eur J Clin Invest 2013; 43(7): 758-65.
89. Holmes DR. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg 1995; 21(5): 761- 71.
90. Thompson MM. Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1996; 11(4): 464-9.
91. Kobayashi M. Expression of angiogenesis and angiogenic factors in human aortic vascular disease. J Surg Res 2002; 106(2): 239-45.
92. Choke E, Cockerill GW, Dawson J, et al. Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice. J Vasc Surg 2010; 52(1): 159- 166.
93. Paik DC, Fu C, Bhattacharya J, Tilson MD. Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 2004; 36(6): 524-33.
94. Choke E. Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol 2006; 26(9): 2077-82.
95. Ferrara N. Discovery and development of bevacizumab, an anti- VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3(5): 391-400.
96. Kaneko H. Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res 2011; 91(2): 358-67.
97. Baek SU, Kwon SI, Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report. J Med Case Rep 2014; 8: 48.
98. Emeto TI, Moxon JV, Rush C, Woodward L, Golledge J. Relevance of urocortins to cardiovascular disease. J Mol Cell Cardiol 2011; 51(3): 299-307.
99. Walczewska J, Dzieza-Grudnik A, Siga O, Grodzicki T. The role of urocortins in the cardiovascular system. J Physiol Pharmacol 2014; 65(6): 753-66.
100. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 2004; 106(4): 383-8.
101. Hasegawa A, Sato K, Shirai R, et al. Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo. PLoS One 2014; 9(12): e110866.
102. Emeto TI, Moxon JV, Biros E, et al. Urocortin 2 is associated with abdominal aortic aneurysm and mediates anti-proliferative effects on vascular smooth muscle cells via corticotrophin releasing factor receptor 2. Clin Sci (Lond) 2014; 126(7): 517-27.
103. Rush C, Nyara M, Moxon JV, et al. Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics 2009; 10: 298.
104. Honjo T, Inoue N, Shiraki R, et al. Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res 2006; 43(2): 131-8.
105. Bale TL, Giordano FJ, Hickey RP, et al. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 2002; 99(11): 7734-9.